IMMX
Immix Biopharma·NASDAQ
--
--(--)
--
--(--)
3.85 / 10
Netural
Fund flow is strong (7.7/10) with ~49% inflow across all investor sizes, though trends are negative. Analyst consensus is 100% Buy from a single analyst, but historical performance is poor and the stock has fallen 10% recently, indicating mixed confidence.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-09
InstitutionCitizens
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for IMMX?
- IMMX holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.85/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
